Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025

Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 

Read more at globenewswire.com